Phaseline

Companies › Voyager Therapeutics

Voyager Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VY7523
Monoclonal antibody targeting pathological tau
MAPTPhase 1Alzheimer's Disease (AD)May 2027
VY1706
AAV9-delivered progranulin (GRN) gene therapy
GRNPhase 1Alzheimer s DiseaseApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06874621VY7523Phase 1Alzheimer's Disease (AD)NeurologyMay 2027
NCT07764146VY1706Phase 1Alzheimer s DiseaseNeurologyApr 2029

From the company's SEC filings

Cash and short-term investments of $132m on 2026-09-30; operating cash outflow about $106m a year; runway about 15 months at that burn, to Dec 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MAPT (1) GRN (1)

Companies with the same targets

Eli Radiopharma Bristol-Myers Squibb Roche Amyloid Solution Arrowhead Pharmaceuticals Nuravax Oligomerix UCB Biopharma SRL Prevail Therapeutics AviadoBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.